Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients
Status:
Not yet recruiting
Trial end date:
2023-05-10
Target enrollment:
Participant gender:
Summary
The purpose is to evaluate the effectiveness and safety of fosaprepitant plus ondansetron
with dexamethasone or placebo plus ondansetron with dexamethasone in preventing
chemotherapy-induced nausea and vomiting (CINV) with MEC/HE multi-day chemotherapy in
children with solid tumors.